Total Payments
$756,324
2024 Payments
$24,793
Companies
72
Transactions
1,840
Medicare Patients
6,795
Medicare Billing
$758,301
Payment Breakdown by Category
Research$733,213 (96.9%)
Food & Beverage$20,323 (2.7%)
Other$2,368 (0.3%)
Education$420.76 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $733,213 | 9 | 96.9% |
| Food and Beverage | $20,323 | 1,787 | 2.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,368 | 3 | 0.3% |
| Education | $420.76 | 41 | 0.1% |
Payments by Type
Research
$733,213
9 transactions
General
$23,112
1,831 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $733,213 | 9 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $3,114 | 52 | $0 (2024) |
| Amgen Inc. | $2,704 | 241 | $0 (2024) |
| ABBVIE INC. | $1,802 | 169 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,651 | 59 | $0 (2024) |
| Novo Nordisk Inc | $1,341 | 120 | $0 (2024) |
| PFIZER INC. | $1,027 | 155 | $0 (2024) |
| GlaxoSmithKline, LLC. | $985.14 | 88 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $976.75 | 109 | $0 (2024) |
| Merck Sharp & Dohme LLC | $877.51 | 68 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,793 | 183 | Eli Lilly and Company ($22,098) |
| 2023 | $3,713 | 247 | Eli Lilly and Company ($560.01) |
| 2022 | $15,030 | 216 | Eli Lilly and Company ($9,953) |
| 2021 | $220,192 | 241 | Eli Lilly and Company ($217,448) |
| 2020 | $485,339 | 192 | Eli Lilly and Company ($483,154) |
| 2019 | $2,443 | 253 | Amgen Inc. ($555.79) |
| 2018 | $2,212 | 239 | Amgen Inc. ($403.47) |
| 2017 | $2,604 | 269 | Amgen Inc. ($364.45) |
All Payment Transactions
1,840 individual payment records from CMS Open Payments — Page 1 of 74
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $39.45 | General |
| Category: SURGERY | ||||||
| 12/19/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $8.96 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/17/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $13.28 | General |
| Category: Inflammation | ||||||
| 12/16/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $14.95 | General |
| Category: PSYCHIATRY | ||||||
| 12/16/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $0.36 | General |
| Category: PSYCHIATRY | ||||||
| 12/13/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $19.25 | General |
| Category: Bone Health | ||||||
| 12/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.20 | General |
| Category: DIABETES | ||||||
| 12/11/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/10/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.95 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/09/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $10.66 | General |
| Category: NEUROSCIENCE | ||||||
| 12/02/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $22.22 | General |
| Category: NEUROSCIENCE | ||||||
| 11/20/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: Gastroenterology | ||||||
| 11/19/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $16,298.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | ||||||
| 11/19/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: PSYCHIATRY | ||||||
| 11/19/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.26 | General |
| Category: DIABETES | ||||||
| 11/18/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.68 | General |
| Category: NEUROSCIENCE | ||||||
| 11/15/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $11.81 | General |
| Category: Bone Health | ||||||
| 11/13/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $19.27 | General |
| Category: PSYCHIATRY | ||||||
| 11/13/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $12.52 | General |
| Category: Inflammation | ||||||
| 11/05/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $18.01 | General |
| Category: NEUROSCIENCE | ||||||
| 10/31/2024 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug), FANAPT | Food and Beverage | In-kind items and services | $28.29 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 10/28/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: PSYCHIATRY | ||||||
| 10/25/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: PAIN | ||||||
| 10/22/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $23.62 | General |
| Category: CARDIOVASCULAR | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $575,730 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | Eli Lilly and Company | $124,871 | 2 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | Eli Lilly and Company | $16,298 | 1 |
| A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $9,953 | 1 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $6,360 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 1,727 | 2,884 | $347,084 | $184,001 |
| 2022 | 19 | 1,617 | 2,881 | $381,596 | $190,108 |
| 2021 | 22 | 1,770 | 3,292 | $391,820 | $192,692 |
| 2020 | 25 | 1,681 | 3,236 | $375,420 | $191,501 |
Total Patients
6,795
Total Services
12,293
Medicare Billing
$758,301
Procedure Codes
88
All Medicare Procedures & Services
88 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 300 | 619 | $83,565 | $49,665 | 59.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 209 | 209 | $31,350 | $25,690 | 81.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 158 | 262 | $54,842 | $23,430 | 42.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 177 | 366 | $53,391 | $21,982 | 41.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 174 | 254 | $25,400 | $14,300 | 56.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 101 | 126 | $23,562 | $12,374 | 52.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 99 | 132 | $14,784 | $8,120 | 54.9% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 77 | 95 | $11,780 | $6,695 | 56.8% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Office | 2023 | 68 | 90 | $8,730 | $5,081 | 58.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 14 | 24 | $8,680 | $3,893 | 44.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 35 | 35 | $8,887 | $3,050 | 34.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 30 | 30 | $4,950 | $2,772 | 56.0% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 12 | 12 | $1,980 | $1,890 | 95.5% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 111 | 186 | $2,920 | $1,771 | 60.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 12 | 12 | $5,616 | $1,589 | 28.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 47 | 72 | $1,800 | $694.89 | 38.6% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 11 | 11 | $1,177 | $531.20 | 45.1% |
| 69210 | Removal of impacted ear wax | Office | 2023 | 12 | 12 | $720.00 | $301.67 | 41.9% |
| 81002 | Urinalysis, manual test | Office | 2023 | 24 | 28 | $560.00 | $95.48 | 17.1% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 12 | 29 | $290.00 | $32.86 | 11.3% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 20 | 80 | $1,600 | $25.58 | 1.6% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 24 | 200 | $500.00 | $16.43 | 3.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 308 | 671 | $90,585 | $53,428 | 59.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 231 | 558 | $113,337 | $43,223 | 38.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 184 | 184 | $27,600 | $22,949 | 83.1% |
About Dr. David Schultz, M.D
Dr. David Schultz, M.D is a Family Medicine healthcare provider based in Evansville, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1912987363.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Schultz, M.D has received a total of $756,324 in payments from pharmaceutical and medical device companies, with $24,793 received in 2024. These payments were reported across 1,840 transactions from 72 companies. The most common payment nature is "" ($733,213).
As a Medicare-enrolled provider, Schultz has provided services to 6,795 Medicare beneficiaries, totaling 12,293 services with total Medicare billing of $758,301. Data is available for 4 years (2020–2023), covering 88 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Evansville, IN
- Active Since 01/20/2006
- Last Updated 02/27/2017
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1912987363
Products in Payments
- REXULTI (Drug) $3,334
- VRAYLAR (Drug) $1,108
- Aimovig (Biological) $837.41
- FARXIGA (Drug) $739.88
- UBRELVY (Drug) $722.41
- NURTEC ODT (Drug) $578.89
- ENTRESTO (Drug) $574.30
- EVENITY (Biological) $563.09
- Ozempic (Drug) $562.48
- TRELEGY ELLIPTA (Drug) $547.32
- Prolia (Biological) $500.05
- JARDIANCE (Drug) $421.44
- FASENRA (Biological) $418.97
- CHANTIX (Drug) $387.84
- DUEXIS (Drug) $368.50
- Enbrel (Biological) $363.86
- Otezla (Drug) $296.14
- XIFAXAN (Drug) $292.69
- JANUVIA (Drug) $275.68
- LINZESS (Drug) $268.72
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Evansville
J Sartore, Md, MD
Family Medicine — Payments: $425,777
Family Medicine $425,777
Dr. Anthony Inzerello, M.d, M.D
Family Medicine — Payments: $315,157
Family Medicine $315,157
Carol Goodman, Md, MD
Family Medicine — Payments: $125,655
Family Medicine $125,655
Randall Oliver, M.d, M.D
Family Medicine — Payments: $75,540
Family Medicine $75,540
David Brougher, M.d, M.D
Family Medicine — Payments: $62,934
Family Medicine $62,934
Dr. Eric Jackson, M.d, M.D
Family Medicine — Payments: $46,422
Family Medicine $46,422